

FORM 51-102F3

MATERIAL CHANGE REPORT

Item 1. Name and Address of Company

LeenLife Pharma International Inc.
Suite 380 – 580 Hornby Street
Vancouver, BC V6C 3B6

Item 2. Date of Material Change

February 25, 2016

Item 3. News Release

News Release dated February 25, 2016 and disseminated to the Vancouver Stockwatch Magazine, B.C. Securities Commission and Alberta Securities Commission, Market News Publishing and other various news dissemination services.

Place of Issuance: Vancouver, British Columbia.

Item 4. Summary of Material Change

The Issuer announces closing of the acquisition of a ninety percent interest in LeenLife Pharma S.A., a private Polish company.

Item 5. Full Description of Material Change

The Issuer is pleased to announce that it has now completed the acquisition of a 90% interest in LeenLife Pharma S.A., a private Polish company, which has developed a process for the isolation of Omega 3 fatty acids from flax seeds. In its news release dated December 2, 2015, the Company announced that it had received final approval from the Canadian Securities Exchange (the "CSE") for the acquisition and proceeded with a change of its name to LeenLife Pharma International Inc. in anticipation of closing the transaction. Due to unforeseen issues with the vendor and the process for completing the share transfer in Poland, which required attendance of signing officers before a notary public in Poland, to have documents properly sworn for filing, the Company was not able to complete the transaction until February 18, 2016.

At closing, the Company provided proof of the issuance of the 12,232,788 shares of the Company (the "Purchase Shares") to the vendors and received 90 shares in LeenLife Pharma S.A., being 90% of the issued shares. The Purchase Shares are subject to a hold period restricting them from trading until June 19, 2016 as well as being subject to the provisions of a regulatory escrow agreement to be administered by the Company's transfer agent, that provides for the release from escrow of 10% of the Purchase Shares at closing, with the remaining 90% being

released over three years at the rate of 15% every six months. The purchase consideration payable by the Company also includes a cash payment in the order of \$563,000 due on or before May 31, 2016, which date was mutually agreed between the parties at closing.

A finder's fee of up to 3% of the equity portion of the purchase price will be paid by the Company in shares in its capital in connection with the transaction.

Item 6. Reliance on Subsection 7.1(2) or (3) of National Instrument 51-102

The Issuer is not relying on Subsection 7.1(2) or (3) of National Instrument 51-102.

Item 7. Omitted Information

There is no omitted information.

Item 8. Executive Officer

Stanley Lis, CEO - (604) 764-0518

Item 9. Date of Report

Dated at the City of Vancouver, in the Province of British Columbia, this 2nd day of March, 2016.

"Stan Lis"

Stan Lis, President & CEO